We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease.
- Authors
Ritchie, Craig W.; Russ, Tom C.; Banerjee, Sube; Barber, Bob; Boaden, Andrew; Fox, Nick C.; Holmes, Clive; Isaacs, Jeremy D.; Leroi, Ira; Lovestone, Simon; Norton, Matt; O'Brien, John; Pearson, Jim; Perry, Richard; Pickett, James; Waldman, Adam D.; Wong, Wai Lup; Rossor, Martin N.; Burns, Alistair
- Abstract
Since the publication of this article [1], it has come to the attention of the authors that information for one of the authors was not included in the competing interests section. Craig Richie has declared potential competing interests with the following companies; Janssen, Eisai, Pfizer, Eli Lilly, Roche Diagnostics, Boeringher Ingleheim, Novartis, AC Immune, Ixico, Aridhia, Amgen, Berry Consultants, Lundbeck, Sanofi, Quintiles (IQVIA) and Takeda. The full competing interests section for this article can be found below.
- Subjects
ELI Lilly &; Co.; NOVARTIS AG
- Publication
Alzheimer's Research & Therapy, 2018, Vol 10, Issue 1, pN.PAG
- ISSN
1758-9193
- Publication type
Correction Notice
- DOI
10.1186/s13195-018-0372-0